The multi-award winning Sheffield business was the only orthopaedics company invited to the three-city mission organized by the Department for International Trade, which included a Royal reception.
JRI Orthopaedics UK general manager Alistair Wheatley said: “It was a very interesting and useful mission with some excellent contacts made.
“JRI Orthopaedics has a long history of innovation, manufacturing excellence, supporting cutting-edge research and working in partnership with the NHS to deliver solutions that bring about real efficiencies and patient benefits.
“India’s healthcare market is estimated to grow to $280 billion by 2020. With its recent commitment to developing 100 smart cities across the country, demand for innovative healthcare solutions in the Indian healthcare system has never been higher.”
The four-day trade mission to commemorate the 70th anniversary of the NHS, was led by Sir Malcolm Grant, Chairman of NHS England, CEO of NHS Digital Sarah Wilkinson and the Minister of State for Trade and Export Promotion Baroness Fairhead.
Delegates from NHS Trusts and health care companies visited New Dehli, Mumbai and Hyderabad to hear from and meet senior managers from Indian hospitals, medical institutes, colleges and business. There was also a reception for HRH The Prince Edward, Earl of Wessex.
JRI Orthopaedics is based at a state-of-the-art manufacturing facility at Chapeltown and has world-class expertise in the design, development and manufacture of orthopaedic implants and surgical instruments.
Founded on innovation, it was the first company in world orthopedics to produce a hip implant with a Hydroxyapatite coating enabling a biological bond with the patient’s bone and so the prospect of a hip for life.
JRI Orthopaedics’s current expanding product portfolio and orthopaedic systems are designed to streamline the delivery of the best solutions in joint reconstruction, repair and regeneration.
Uniquely, the company is wholly owned by the charity Orthopaedic Research UK (ORUK) and has donated millions to fund world class research into bone and joint disease.